drugset / Trial / NCT00713934

Autologous Bone Marrow Stem Cells in Cirrhosis Patients

NCT00713934

RandomizedParallel-groupSingle-blindTreatment

Summary

Liver cirrhosis (LC) is the end stage of chronic liver disease. The liver transplantation is one of the only effective therapies available to such patients. However, lack of donors, surgical complications, rejection, and high cost are it's serious problems. The potential for stem cells in bone marrow (BM) to differentiate into hepatocytes cells was recently confirmed. Moreover, BMC transplantation has been performed to treat hematological diseases, and several clinical studies have applied BMC injection to induce regeneration of myocardium and blood vessels. In this study we will evaluate safety and feasibility of autologous bone marrow mono nuclear (BM-MNC) and enriched CD133+ hematopoietic stem cell transplantation through the portal vein in patients with decompensate cirrhosis.

Timeline

Start
2008-01
Primary completion
2009-01
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BM-MNC Cell therapy Other
Subject CD133 Unknown Other